Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.87 |
| ▸ | WDR77 | Q9BQA1 | 15/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15824151 | 0.93 | PRMT5 (1.00) | PRMT5WDR77MAPK1 | |
| SCHEMBL15917744 | 0.93 | PRMT5 (1.00) | PRMT5WDR77MAPK1 | |
| SCHEMBL15826024 | 0.93 | PRMT5 (1.00) | PRMT5WDR77MAPK1 | |
| SCHEMBL17300963 | 0.87 | PRMT5 (0.76) | PRMT5WDR77KDM4EMAPK1GAA | |
| SCHEMBL17300943 | 0.83 | PRMT5 (0.88) | PRMT5WDR77 | |
| SCHEMBL17300931 | 0.83 | PRMT5 (0.88) | PRMT5WDR77 | |
| SCHEMBL17300927 | 0.83 | PRMT5 (0.88) | PRMT5WDR77 | |
| SCHEMBL17300928 | 0.83 | PRMT5 (0.88) | PRMT5WDR77 | |
| SCHEMBL19957633 | 0.83 | PRMT5 (0.88) | PRMT5WDR77 | |
| SCHEMBL17300940 | 0.83 | PRMT5 (0.88) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | NOVARTIS AG (CH) | 2019-11-19 | — | — | US | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| WO-2016089883-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479997-B2 | Compositions and methods for diagnosis and treatment of prostate cancer | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 50/4885KDM4E 94/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 54/4885KDM4E 33/4885 |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 50/4885KDM4E 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.